← Back to Search

Nitroglycerin for Migraine

N/A
Recruiting
Led By Andrew Kobets, MD
Research Sponsored by Montefiore Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 20 minutes
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether a new imaging tool can help show changes in blood vessels during migraine headaches.

Who is the study for?
This trial is for adults with a neurologist-confirmed diagnosis of migraine, experiencing migraines at least twice a month and not responding to standard treatments. Participants must have had stable neurological exams in the past 6 months and be willing to undergo angiography. Pregnant women, children, those with severe pulmonary or cardiac conditions, recent caffeine or alcohol intake, or on certain medications are excluded.
What is being tested?
The study aims to understand migraine pain by using nitroglycerin-induced dilation of blood vessels during an angiogram to simulate migraine symptoms. Researchers will observe changes in vessel flow during headache attacks which could inform future treatment strategies.
What are the potential side effects?
Nitroglycerin can cause headaches resembling migraines (which is part of the study), as well as dizziness, flushing, low blood pressure, and increased heart rate. It's important that participants report any discomfort they experience during the procedure.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~20 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and 20 minutes for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Migraine
Secondary study objectives
Adverse reactions
Artery dilation
Migraine log follow-up post-procedure: aggravating factor measure
+16 more

Side effects data

From 2019 Phase 4 trial • 66 Patients • NCT02209636
38%
Non-serious adverse events
3%
Hospitalization
100%
80%
60%
40%
20%
0%
Study treatment Arm
Lanthanum Carbonate
Placebo
Placebo- Phosphorus Balance Sub-study
Lanthanum Carbonate- Phosphorus Balance Sub-study

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Migraine InterventionExperimental Treatment1 Intervention
Subjects who will be administered 200 micrograms of nitroglycerin once into branches of their external carotid artery to determine the role of dilation of this artery to cause migraine-like pain

Find a Location

Who is running the clinical trial?

Montefiore Medical CenterLead Sponsor
458 Previous Clinical Trials
588,604 Total Patients Enrolled
11 Trials studying Migraine
1,972 Patients Enrolled for Migraine
Andrew Kobets, MDPrincipal InvestigatorMontefiore Medical Center
David J Altschul, MDPrincipal InvestigatorMontefiore Medical Center
1 Previous Clinical Trials
200 Total Patients Enrolled

Media Library

Nitroglycerin Clinical Trial Eligibility Overview. Trial Name: NCT03026101 — N/A
Migraine Research Study Groups: Migraine Intervention
Migraine Clinical Trial 2023: Nitroglycerin Highlights & Side Effects. Trial Name: NCT03026101 — N/A
Nitroglycerin 2023 Treatment Timeline for Medical Study. Trial Name: NCT03026101 — N/A
~2 spots leftby Jun 2026